The market is pricing the core business at nearly zero
Elliott Management has taken a quiet but consequential position in Bio-Rad Laboratories, a medical diagnostics company whose stock has lost more than two-thirds of its value since the pandemic era ended. The activist firm's interest centers on a striking arithmetic: Bio-Rad holds a stake in German supplier Sartorius worth roughly $5 billion, nearly matching the company's entire $6.6 billion market value, as if the market has decided the underlying business is worth almost nothing. This is the oldest tension in investing — between what a thing is worth and what the world is willing to pay for it — and Elliott is betting that gap cannot hold forever, even if a founding family's grip on voting power means the path to resolution will be neither swift nor simple.
- Bio-Rad's shares have collapsed more than 70 percent from their 2021 peak, and a first-quarter earnings miss paired with a lowered full-year guidance cut has deepened the sense that the company is adrift.
- The hidden pressure point is a $5 billion Sartorius stake sitting inside a $6.6 billion company — a valuation absurdity that implies the market is pricing Bio-Rad's actual operations at near zero or below.
- Elliott's entry is complicated by the founding family's majority voting control, meaning no boardroom coup is possible and any change must be negotiated across generational loyalties rather than forced through share accumulation.
- The firm holds positions in both Bio-Rad and Sartorius, hinting at a layered strategic thesis tied to the long-term rise of biologic drugs and a recovering biopharma spending cycle.
- The stock surged nearly 13 percent on news of Elliott's involvement, signaling that the market senses pressure building — though whether the release valve comes from inside the family or from an outside acquirer remains unresolved.
Elliott Management has quietly accumulated a stake in Bio-Rad Laboratories, an established but struggling medical diagnostics company whose shares have fallen more than 70 percent from their pandemic-era high of $800. What drew the activist firm's attention is not simply a beaten-down stock — it is a striking hidden asset: Bio-Rad holds a strategic investment in Sartorius, a German pharmaceutical equipment supplier, valued at roughly $5 billion. That single holding represents nearly the entirety of Bio-Rad's $6.6 billion market capitalization, implying that the market is effectively valuing the company's core diagnostics operations at close to nothing.
Bio-Rad's instruments and software serve hospitals, blood banks, and medical laboratories worldwide — essential infrastructure, but operationally troubled. The company's projected 2026 operating margins of 10 to 12 percent look thin against sector peers posting margins above 30 percent, suggesting either inefficiency or a company caught mid-transition. A recent earnings report added to the uncertainty: adjusted earnings missed analyst expectations, and while revenue slightly beat forecasts, the company cut its full-year sales guidance below consensus — the kind of signal that sharpens an activist's focus.
Elliott's position is further complicated by a structural reality: Bio-Rad's founding family controls the majority of voting shares. This is not a company where accumulated stock translates into boardroom leverage. Any push for cost discipline, a strategic sale, or capital returns must be negotiated with a family that has held the company across generations — a dynamic that makes activist campaigns slower and less predictable, even when the financial logic for change is clear.
Adding texture to Elliott's thesis, the firm is also a significant investor in Sartorius itself, suggesting it may be thinking about the relationship between the two companies as the biopharma sector recovers. Improving research and development spending across the industry and accelerating dealmaking could make Bio-Rad attractive to acquirers willing to absorb its operational challenges in exchange for the Sartorius holding and a potential margin turnaround.
The market responded to Elliott's involvement with a 12.94 percent single-day jump in Bio-Rad's stock — a signal that investors believe something will shift. Whether that shift is engineered from within, negotiated with the family, or ultimately triggered by an outside buyer is the question that now hangs over Echo Harbor's financial watchers and the broader life-science investment community alike.
Elliott Management has quietly built a stake in Bio-Rad Laboratories, betting that the medical diagnostics company is sitting on billions in unrealized value that the market has overlooked. The activist investor sees opportunity in a business that has been battered since the pandemic boom ended—shares have collapsed more than 70 percent from their $800 peak in late 2021—but what caught Elliott's attention is not the core business alone. It's what Bio-Rad owns: a strategic investment in Sartorius, a German pharmaceutical and laboratory equipment supplier, valued at roughly $5 billion. That single holding is worth nearly as much as Bio-Rad's entire current market capitalization of $6.6 billion, suggesting the market is pricing the company's actual operations at close to zero, or even assigning them negative value.
Bio-Rad manufactures instruments and software that hospitals, blood banks, and medical laboratories depend on every day. It is a necessary business, but it has become a struggling one. The company's projected operating margins for 2026 sit between 10 and 12 percent—a figure that looks anemic compared to competitors in the sector, many of which post margins exceeding 30 percent. That gap signals either operational inefficiency or a company caught in a difficult transition. Elliott's thesis appears to be that Bio-Rad can be fixed, or that its hidden asset value makes it attractive to a potential buyer willing to take on the turnaround challenge.
The activist's position is complicated, however, by a structural reality that many investors overlook: Bio-Rad's founding family retains majority voting control. This is not a company where Elliott can simply accumulate shares and force a boardroom coup. Any effort to drive strategic or operational changes—whether that means pushing for cost cuts, a sale, or a dividend—will require negotiating with a family that has held the company for generations. That dynamic has historically made activist campaigns messier and less predictable, even when the financial case for change is compelling.
Elliott is also a major investor in Sartorius itself, which adds another layer to the story. The firm views Sartorius as a high-quality business with strong long-term growth prospects, particularly as biologic drugs continue to reshape the pharmaceutical industry. This dual position—holding both Bio-Rad and Sartorius—suggests Elliott may be thinking about the relationship between the two companies, or simply betting that both will benefit as the biopharma sector rebounds.
Bio-Rad's recent earnings offer a mixed picture. In the first quarter, the company reported adjusted earnings of $1.89 per share, missing analyst expectations of $1.98. Sales came in at $592.10 million, beating the consensus forecast of $588.88 million. But the company then lowered its full-year sales guidance, projecting revenue between $2.51 billion and $2.59 billion, down from its prior range of $2.59 billion to $2.62 billion and below the $2.63 billion consensus. That guidance cut is the kind of signal that typically sends activist investors scrambling to understand what went wrong and what can be fixed.
The broader context is shifting in Bio-Rad's favor. The life-science tools and diagnostics industry faced significant headwinds after the pandemic ended and major pharmaceutical companies began restructuring their operations. But conditions have begun to improve as biopharma companies increase research and development spending and dealmaking activity accelerates. That improving backdrop could make Bio-Rad more attractive to potential acquirers, particularly if the company's operational challenges can be attributed to cyclical industry weakness rather than fundamental business problems.
The question now is whether Elliott will be able to move the needle. The firm's exact stake size and specific plans remain unclear, but the math is straightforward: if Bio-Rad can improve its margins toward peer levels while maintaining its Sartorius holding, the stock could have significant upside. If the family proves unwilling to pursue aggressive change, Elliott may have to settle for a slower path to value creation, or wait for an external buyer to make a move. The stock jumped 12.94 percent on the news of Elliott's involvement, suggesting the market believes something will give. Whether that something comes from within or from outside remains to be seen.
Notable Quotes
Elliott views Sartorius as a high-quality company with strong long-term growth prospects, particularly as biologic drugs continue to dominate the pharmaceutical market— People familiar with Elliott's thinking, per Wall Street Journal
The Hearth Conversation Another angle on the story
Why does Elliott think Bio-Rad is worth fixing when the stock has fallen so far?
Because the company owns a $5 billion stake in Sartorius that the market is essentially ignoring. Bio-Rad's entire market cap is only $6.6 billion, so the market is saying the core business is worth almost nothing. Elliott sees either a turnaround opportunity or an acquisition target.
But the margins are terrible—10 to 12 percent when competitors are posting 30 percent or more. That's not just a valuation problem.
Right. That's the real question. Is it a cyclical problem that will fix itself as the biopharma industry spends more, or is it structural? Elliott is betting it's the former, or that a new owner could fix it.
What's the family voting control issue really about?
It means Elliott can't just accumulate shares and force change. The founding family has majority voting power, so any major decision—a sale, a restructuring, a dividend—requires their consent. That makes the activist campaign much harder.
So Elliott might not be able to do what it wants?
Exactly. The firm might have to negotiate with the family, or wait for an external buyer to make an offer that's too good to refuse. Or the family might actually agree that change is necessary.
Why is Elliott also invested in Sartorius?
That's interesting. It could be a separate conviction about Sartorius as a business. Or it could be that Elliott is thinking about the relationship between the two companies—whether Bio-Rad should be holding that stake, or whether there's some strategic angle there.
What happens next?
The market will watch to see if Elliott can pressure the company into action, or if the family blocks it. Meanwhile, improving conditions in biopharma could attract other buyers. Bio-Rad could become a takeover target whether Elliott wants that or not.